Skip to main content
. 2023 Jan 30;15(3):854. doi: 10.3390/cancers15030854

Figure 3.

Figure 3

Kaplan–Meier analysis illustrating overall survival in the PD-1 inhibitors plus sorafenib group and the PD-1 inhibitors plus lenvatinib group in patients with albumin–bilirubin (ALBI) grade 1 (a) and ALBI grade 2 or 3 (b), respectively. PD-1, programmed cell death protein-1.